Jpmorgan Chase & CO Bridge Bio Pharma, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 176,079 shares of BBIO stock, worth $4.44 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
176,079
Previous 366,653
51.98%
Holding current value
$4.44 Million
Previous $11.3 Million
60.66%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding BBIO
# of Institutions
296Shares Held
176MCall Options Held
8.64MPut Options Held
2.84M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY31.1MShares$783 Million45.4% of portfolio
-
Viking Global Investors LP25.1MShares$633 Million2.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.1MShares$354 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$314 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$153 Million67.33% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $3.74B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...